Thank you, Madam Chairperson.
Thank you, Mr. Dal Pan. I appreciate your input today.
I would like to go back to your comments about heparin and pursue the idea of inspection and proper surveillance of drugs that are produced overseas. In the case of heparin, I believe it was a factory in China that resulted in a batch of heparin being contaminated. What does the United States do now, in terms of inspection overseas, to ensure that drugs are safe and free of contaminants?